2013
DOI: 10.1016/s1734-1140(13)71077-6
|View full text |Cite
|
Sign up to set email alerts
|

Effect of infliximab on metabolic disorders induced by Walker-256 tumor in rats

Abstract: The treatment with infliximab ameliorated some changes associated with cachexia, such as the reduction of adipose tissue and body weight, suggesting that TNFα plays a significant role in mediating these changes induced by the tumor. In addition, infliximab tended to improve or had no effect on other metabolic parameters affected by the Walker-256 tumor, suggesting that other mediators or tumor-related events are involved in these disorders.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

3
11
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
10

Relationship

3
7

Authors

Journals

citations
Cited by 14 publications
(14 citation statements)
references
References 47 publications
3
11
0
Order By: Relevance
“…Although the sedentary rats did not exhibit peripheral resistance to insulin during the tumor growth period in the present study, which has been evidenced in similar cancer models in the literature ( Asp et al, 2010 ; Miksza et al, 2013 ), we pointed out several aspects in the interpretation of results that should be considered, such as animal species, associated insults, inoculated tissue and volume, experimental time, cellular viability, exercise protocol, drug administration, among others. The highly variable biological due these environmental interactions ( Weiss and Harlos, 1979 ) and the lack of pure strains of cells, has been demonstrated long time ago, as a severe handicap to the study of malignant growths, particularly in Walker 256 tumor experimental model ( Earle, 1935 ; Moraes et al, 2000 ).…”
Section: Discussionsupporting
confidence: 65%
“…Although the sedentary rats did not exhibit peripheral resistance to insulin during the tumor growth period in the present study, which has been evidenced in similar cancer models in the literature ( Asp et al, 2010 ; Miksza et al, 2013 ), we pointed out several aspects in the interpretation of results that should be considered, such as animal species, associated insults, inoculated tissue and volume, experimental time, cellular viability, exercise protocol, drug administration, among others. The highly variable biological due these environmental interactions ( Weiss and Harlos, 1979 ) and the lack of pure strains of cells, has been demonstrated long time ago, as a severe handicap to the study of malignant growths, particularly in Walker 256 tumor experimental model ( Earle, 1935 ; Moraes et al, 2000 ).…”
Section: Discussionsupporting
confidence: 65%
“…Walker 256 tumour‐bearing rats and other cancer animal models have tissue insulin resistance, which indicates that more glucose is available for the tumour (Miksza et al . ; Hung et al . ; Porporato, ).…”
Section: Discussionmentioning
confidence: 99%
“…MT-102 (Espindolol), a novel anabolic/catabolic transforming agent, was used to treat subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer in clinical phase II. Infliximab, anti-TNFα monoclonal antibody, was applied to treat cancer-related cachexia in subjects with pancreatic cancer in clinical phase II ( Wiedenmann et al, 2008 ; Arruda et al, 2010 ; Gueta et al, 2010 ; Miksza et al, 2013 ). Although these agents have entered into clinical evaluation, it is increasingly evident that a single therapy may not be sufficient to prevent or ameliorate cancer cachexia due to the complexity of this syndrome.…”
Section: Introductionmentioning
confidence: 99%